Business Information
The group's principal activities are to discover, in-license, develop and commercialize novel drug candidates for central nervous system, cardiovascular and urological disorders. The group has six product candidates in clinical trails. The products of the group include indiplon, ocinaplon, bicifadine, dov 216,303, dov 21,947 and dov diltiazem. These products will be used for the treatment of insomnia, anxiety disorders, pain, depression and angina and hypertension. The group also has two compounds in preclinical development namely, dov 102,677 and dov 51,892, for the potential treatment of Parkinson's disease, restless leg syndrome, attention deficit disorder and anxiety disorders including panic.
|
|
Name |
Title
|
Email
|
| Arnold Lippa | Co - Founder, Exec. Chmn., Advisor | N/A | | Robert Cancro | Co - Founder, Chmn. - Scientific Advisory Board | N/A | | Phil Skolnick | Pres., Chief Scientific Officer | N/A | | William Kaltnecker | Chief Accounting Officer, Controller | N/A | | Warren Stern | Sr. VP - Drug Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 25,951 | (38,368) | | 2005 | 8,647 | (52,968) | | 2004 | 2,542 | (32,921)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
